Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Lisata Therapeutics to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations.
Analyst Recommendations
This is a summary of current recommendations and price targets for Lisata Therapeutics and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Lisata Therapeutics Competitors | 9839 | 15125 | 45450 | 1588 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 103.02%. Given Lisata Therapeutics’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics has less favorable growth aspects than its competitors.
Profitability
This table compares Lisata Therapeutics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -116.08% | -90.55% |
| Lisata Therapeutics Competitors | -12,346.73% | -197.60% | -30.56% |
Institutional and Insider Ownership
8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 8.4% of Lisata Therapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Lisata Therapeutics and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lisata Therapeutics | $100,000.00 | -$16.59 million | -0.63 |
| Lisata Therapeutics Competitors | $740.81 million | $14.11 million | -15.26 |
Lisata Therapeutics’ competitors have higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Lisata Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Lisata Therapeutics’ competitors have a beta of 1.10, indicating that their average stock price is 10% more volatile than the S&P 500.
Summary
Lisata Therapeutics competitors beat Lisata Therapeutics on 10 of the 13 factors compared.
Lisata Therapeutics Company Profile
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
